Wall Street analysts forecast that Waters Co. (NYSE:WAT) will post earnings of $2.13 per share for the current fiscal quarter, according to Zacks Investment Research. Five analysts have made estimates for Waters’ earnings, with the highest EPS estimate coming in at $2.15 and the lowest estimate coming in at $2.11. Waters reported earnings per share of $1.92 during the same quarter last year, which would indicate a positive year-over-year growth rate of 10.9%. The firm is scheduled to announce its next quarterly earnings results before the market opens on Tuesday, October 29th.
On average, analysts expect that Waters will report full-year earnings of $9.01 per share for the current financial year, with EPS estimates ranging from $8.95 to $9.05. For the next financial year, analysts expect that the firm will report earnings of $10.14 per share, with EPS estimates ranging from $9.82 to $10.82. Zacks Investment Research’s EPS averages are an average based on a survey of research firms that cover Waters.
Waters (NYSE:WAT) last announced its quarterly earnings data on Tuesday, July 30th. The medical instruments supplier reported $2.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.11 by $0.03. Waters had a return on equity of 50.64% and a net margin of 24.09%. The company had revenue of $599.20 million for the quarter, compared to analysts’ expectations of $601.46 million. During the same quarter in the prior year, the business posted $1.95 EPS. The business’s revenue was up .5% compared to the same quarter last year.
Shares of Waters stock opened at $219.08 on Friday. Waters has a 12-month low of $167.93 and a 12-month high of $255.21. The stock has a market cap of $14.40 billion, a P/E ratio of 26.43, a P/E/G ratio of 2.43 and a beta of 1.07. The company has a quick ratio of 2.07, a current ratio of 2.65 and a debt-to-equity ratio of 2.00. The business’s 50 day moving average is $220.75 and its 200-day moving average is $216.85.
Several hedge funds have recently bought and sold shares of the stock. Invesco Ltd. increased its holdings in shares of Waters by 20.3% during the 2nd quarter. Invesco Ltd. now owns 775,740 shares of the medical instruments supplier’s stock worth $166,971,000 after acquiring an additional 130,671 shares during the last quarter. Mackenzie Financial Corp increased its holdings in shares of Waters by 252.8% during the 2nd quarter. Mackenzie Financial Corp now owns 638,075 shares of the medical instruments supplier’s stock worth $137,339,000 after acquiring an additional 457,218 shares during the last quarter. Mawer Investment Management Ltd. increased its holdings in shares of Waters by 7.1% during the 2nd quarter. Mawer Investment Management Ltd. now owns 532,219 shares of the medical instruments supplier’s stock worth $114,531,000 after acquiring an additional 35,506 shares during the last quarter. UBS Asset Management Americas Inc. increased its holdings in shares of Waters by 2.3% during the 2nd quarter. UBS Asset Management Americas Inc. now owns 472,001 shares of the medical instruments supplier’s stock worth $101,593,000 after acquiring an additional 10,728 shares during the last quarter. Finally, Jensen Investment Management Inc. increased its holdings in shares of Waters by 1.4% during the 2nd quarter. Jensen Investment Management Inc. now owns 446,637 shares of the medical instruments supplier’s stock worth $96,134,000 after acquiring an additional 5,976 shares during the last quarter. 95.01% of the stock is currently owned by institutional investors and hedge funds.
Waters Corporation, a specialty measurement company, provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments, Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans.
Featured Story: How to track put option volume
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Waters Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Waters and related companies with MarketBeat.com's FREE daily email newsletter.